vs
Side-by-side financial comparison of Enpro Inc. (NPO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Enpro Inc. is the larger business by last-quarter revenue ($295.4M vs $177.4M, roughly 1.7× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -10.8%, a 12.5% gap on every dollar of revenue. On growth, Enpro Inc. posted the faster year-over-year revenue change (14.3% vs 5.0%). Over the past eight quarters, Enpro Inc.'s revenue compounded faster (7.1% CAGR vs -0.2%).
Enpro is a US-based industrial technology company that designs and manufactures products and materials for technology-intensive sectors. The company serves industries such as semiconductors, aerospace, power generation, heavy-duty trucking, agricultural machinery, chemical processing, pulp and paper, and life sciences from 61 primary manufacturing facilities located in 12 countries, worldwide. It is organized under three segments: Sealing Technologies, Advanced Surface Technologies, and Engin...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
NPO vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.4M | $177.4M |
| Net Profit | $-32.0M | $2.9M |
| Gross Margin | 42.1% | — |
| Operating Margin | 11.2% | 3.9% |
| Net Margin | -10.8% | 1.6% |
| Revenue YoY | 14.3% | 5.0% |
| Net Profit YoY | -330.2% | — |
| EPS (diluted) | $-1.50 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $295.4M | $196.9M | ||
| Q3 25 | $286.6M | $179.5M | ||
| Q2 25 | $288.1M | $181.1M | ||
| Q1 25 | $273.2M | $168.9M | ||
| Q4 24 | $258.4M | $187.3M | ||
| Q3 24 | $260.9M | $168.6M | ||
| Q2 24 | $271.9M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-32.0M | — | ||
| Q3 25 | $21.6M | $5.4M | ||
| Q2 25 | $26.4M | $-4.8M | ||
| Q1 25 | $24.5M | $4.8M | ||
| Q4 24 | $13.9M | — | ||
| Q3 24 | $19.8M | $-143.5M | ||
| Q2 24 | $26.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 42.1% | 79.5% | ||
| Q3 25 | 41.9% | 80.9% | ||
| Q2 25 | 43.3% | 77.4% | ||
| Q1 25 | 43.3% | 79.7% | ||
| Q4 24 | 42.3% | 78.7% | ||
| Q3 24 | 42.3% | 76.9% | ||
| Q2 24 | 43.8% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 11.2% | 1.2% | ||
| Q3 25 | 14.3% | 3.5% | ||
| Q2 25 | 15.9% | 4.7% | ||
| Q1 25 | 15.3% | 1.2% | ||
| Q4 24 | 12.5% | 13.2% | ||
| Q3 24 | 13.1% | -82.8% | ||
| Q2 24 | 17.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -10.8% | — | ||
| Q3 25 | 7.5% | 3.0% | ||
| Q2 25 | 9.2% | -2.7% | ||
| Q1 25 | 9.0% | 2.8% | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 7.6% | -85.1% | ||
| Q2 24 | 9.8% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-1.50 | $0.05 | ||
| Q3 25 | $1.01 | $0.12 | ||
| Q2 25 | $1.25 | $-0.11 | ||
| Q1 25 | $1.15 | $0.10 | ||
| Q4 24 | $0.65 | $0.38 | ||
| Q3 24 | $0.94 | $-3.11 | ||
| Q2 24 | $1.27 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $114.7M | $144.3M |
| Total DebtLower is stronger | $655.3M | — |
| Stockholders' EquityBook value | $1.5B | $653.9M |
| Total Assets | $2.7B | $1.2B |
| Debt / EquityLower = less leverage | 0.42× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $114.7M | $238.4M | ||
| Q3 25 | $132.9M | $246.3M | ||
| Q2 25 | $107.1M | $445.9M | ||
| Q1 25 | $240.3M | $493.6M | ||
| Q4 24 | $236.3M | $484.6M | ||
| Q3 24 | $206.9M | $453.8M | ||
| Q2 24 | $175.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $655.3M | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $640.1M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.5B | $693.1M | ||
| Q3 25 | $1.5B | $727.2M | ||
| Q2 25 | $1.5B | $757.8M | ||
| Q1 25 | $1.5B | $798.5M | ||
| Q4 24 | $1.4B | $778.3M | ||
| Q3 24 | $1.5B | $749.6M | ||
| Q2 24 | $1.4B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.7B | $1.3B | ||
| Q3 25 | $2.4B | $1.3B | ||
| Q2 25 | $2.4B | $1.5B | ||
| Q1 25 | $2.5B | $1.6B | ||
| Q4 24 | $2.5B | $1.6B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.5B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.42× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.45× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NPO
| Sealing Technologies Segment | $187.0M | 63% |
| General Industrial | $71.3M | 24% |
| Power Generation | $19.9M | 7% |
| Oiland Gas Market | $15.0M | 5% |
| Semiconductors | $2.2M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
